Six malignancies trace directly back to persistent infection with high-risk human papillomavirus strains, including cervical, oropharyngeal, anal, vulvar, vaginal, and penile cancers. Together they account for roughly 5% of every cancer diagnosis worldwide. In the United States alone, about 36,000 HPV-linked cases appear each year, and oropharyngeal cancer has overtaken cervical cancer among men.
This article explores the six cancers tied to HPV, breaking down how high-risk viral strains drive each one and why risk profiles differ between men and women.
HPV and Cancer Begin With a Common Viral Infection
Human papillomavirus passes through intimate skin-to-skin contact, often during sex, and almost always clears on its own within one to two years. An HPV-positive test on routine screening means the virus is present, not that cancer has developed. Your immune system still has every chance to eliminate it. The U.S. Centers for Disease Control and Prevention (CDC) estimates that nearly every sexually active person picks up some form of HPV at some point.
Cancer becomes possible only when a high-risk strain lingers for years inside epithelial cells, the thin tissue layers lining the cervix, throat, anus, and genital tract. The virus inserts two troublesome oncoproteins called E6 and E7, which disable the tumor suppressor proteins that normally stop runaway cell growth. Without those guards, abnormal cells can slowly accumulate the genetic damage that defines cancer.
Because the body usually clears HPV before any cellular damage occurs, infection alone is common while cancer remains rare. Worldwide, HPV causes about 5% of all cancer cases, translating to roughly 36,000 cancer diagnoses each year in the United States alone.
Six Distinct Cancers Now Linked to HPV
HPV is responsible for several cancers beyond the cervix, and the full list matters for anyone mapping their own risk. The World Health Organization (WHO) and the National Cancer Institute (NCI) both recognize six cancers with a confirmed viral origin, each tied to specific high-risk strains and patient demographics.
Cervical and Other Female Reproductive Cancers
Cervical cancer remains the most recognized HPV-driven malignancy, with virtually 100% of cases tied to infection. Vaginal cancer draws about 75% of cases from HPV, and a majority of vulvar cancers carry the same viral fingerprint. These three sites are where HPV screening and vaccination have made the largest historical impact.
Oropharyngeal, Anal, and Penile Cancers
Tumors of the tonsils and base of the tongue, the oropharynx, account for roughly 70% of HPV-linked head and neck cancers and represent the fastest-rising HPV cancer in American men. Anal cancer is HPV-positive in about 90% of diagnoses, with elevated rates among men who have sex with men and people living with HIV. Penile cancer carries an HPV association in roughly 60% of cases, a statistic that rarely surfaces in standard male health discussions.
| Cancer Type | Approximate HPV Attribution | Primary High-Risk Strain(s) |
|---|---|---|
| Cervical | ~100% | HPV 16, 18 |
| Oropharyngeal (tonsil, base of tongue) | ~70% | HPV 16 |
| Anal | ~90% | HPV 16 |
| Vulvar | Majority of cases | HPV 16, 18 |
| Vaginal | ~75% | HPV 16, 18 |
| Penile | ~60% | HPV 16, 18 |
High-Risk HPV Strains Drive Most Cancer Cases
More than 200 HPV strains have been identified, but only about a dozen are classified as oncogenic, meaning they carry meaningful cancer risk. HPV 16 alone causes the majority of HPV-related cancers across every anatomical site, with HPV 18 close behind. Together, these two strains account for roughly 70% of cervical cancers and a similarly dominant share of the other five cancers on the list.
Strains 31, 33, 45, 52, and 58 round out the high-risk group targeted by the current 9-valent HPV vaccine. Together with 16 and 18, they cover the seven strains behind approximately 90% of HPV-driven cancers.
Low-Risk Strains Cause Warts, Not Cancer
Strains 6 and 11 are responsible for about 90% of genital warts and most cases of recurrent respiratory papillomatosis, a rare throat condition. These low-risk types almost never progress to cancer, which is why an HPV-positive wart on your hand or genitals is not a cancer warning sign. Distinguishing high-risk from low-risk strains on a lab report matters far more than the mere word “HPV.”
Men and Women Face Different Cancer Risk Profiles
HPV cancer risks split sharply by sex, and most public awareness still centers on the female side of the ledger. Women carry the burden of cervical, vulvar, and vaginal cancers, each tied closely to HPV and each largely preventable through vaccination and routine screening. Men account for the majority of HPV-positive oropharyngeal cases and a meaningful share of anal cancers, yet no organized national screening program exists for either site in most countries.
In the United States, HPV-linked cancer incidence approaches 36,000 cases per year across both sexes, with the sex breakdown shifting as oropharyngeal rates climb in men. Roughly 60% of those cases now occur in men, a pattern that has driven recommendations to vaccinate boys alongside girls.
That male skew reshapes who carries the heaviest cancer burden from HPV.
The fastest-rising HPV cancer in American men is now throat cancer, a reversal that has caught many clinicians off guard.
From Infection to Cancer Often Takes a Decade or Longer
Most HPV infections resolve within one to two years before any cellular damage occurs, which is why a single positive test rarely predicts cancer. When malignancy does develop, the timeline from initial infection typically spans 10 to 20-plus years, giving screening programs an unusually wide window to catch precancerous changes. This long latency is also why vaccination works best before sexual debut, but still helps adults well into their 40s.
Early Warning Signs by Cancer Site
Because HPV-driven cancers develop slowly and often without pain, the first clue is frequently subtle. Watch for an unexplained sore throat, a persistent neck lump, or trouble swallowing that lasts beyond two weeks. Anal cancer can announce itself through bleeding, itching, or pain during bowel movements. Vulvar and penile cancers often start as visible lesions or scaly skin changes that do not heal. Post-coital bleeding remains the classic cervical warning sign.
- Throat symptoms: Persistent sore throat, ear pain, or one-sided neck swelling lasting more than two weeks
- Anal symptoms: Bleeding, itching, or a palpable lump near the anus
- Vulvar or vaginal symptoms: Persistent itching, bleeding, or visible skin lesions
- Penile symptoms: A sore, ulcer, or scaly rash that does not resolve
- Cervical symptoms: Bleeding between periods, after sex, or after menopause
Vaccination, Screening, and Lifestyle Choices Cut Risk Substantially
Prevention works on three fronts: vaccination, screening, and behavior change. The 9-valent HPV vaccine (Gardasil 9) protects against seven high-risk strains and the two that cause genital warts, covering the viral culprits behind roughly 90% of HPV cancers. The CDC recommends vaccination routinely through age 26, and shared clinical decision-making now extends that protection through age 45 for both sexes.
Routine Screening Catches Problems Early
Cervical screening with Pap and HPV co-testing every three to five years catches precancerous changes before they progress to invasive disease. Anal Pap testing and oral examinations are emerging options for specific high-risk groups, particularly men with HIV, men who have had receptive anal intercourse, and people with a history of HPV-related disease. The U.S. Preventive Services Task Force (USPSTF) continues to evaluate anal screening recommendations as evidence accumulates.
Behaviors That Lower Your Odds
- Condom use: Reduces, though does not eliminate, HPV transmission during vaginal, anal, and oral sex
- Smoking cessation: Tobacco use doubles the risk of persistence and progression of HPV infection
- Fewer lifetime partners: Limits cumulative exposure to high-risk strains
- Circumcision (in men): Reduces penile HPV acquisition by roughly 30%
Living HPV-Positive Without Cancer Demands a Monitoring Roadmap
An HPV-positive result with normal cytology, meaning no abnormal cells seen under the microscope, is not a cancer diagnosis. Current guidelines call for repeat co-testing in 12 months rather than immediate intervention, because most infections clear in that window.
An HPV-positive test with normal cytology means “watch and wait,” not “prepare for the worst.”
Specialist referral clarifies the next step when findings warrant it. Colposcopy (a magnified cervical exam) is the standard follow-up for abnormal cervical screening. Anoscopy evaluates anal findings. An ENT specialist handles oral or throat symptoms. Survivors of one HPV cancer remain at elevated risk for second HPV cancers and benefit from lifelong surveillance under a clinician familiar with their history.
The Bottom Line
HPV causes six distinct cancers: cervical, vaginal, vulvar, oropharyngeal, anal, and penile. Two strains, 16 and 18, drive the majority of cases. Vaccination, routine screening, and a few behavior changes can prevent most of these diagnoses, even decades after exposure.
FAQ
What types of cancer does HPV cause?
That cancers: cervical, vaginal, vulvar, oropharyngeal (tonsil and base of tongue), anal, and penile. Together these account for about 5% of all cancer cases worldwide, with roughly 36,000 new diagnoses each year in the United States.
Which HPV strains are most likely to cause cancer?
HPV 16 and HPV 18 are responsible for the majority of HPV-related cancers across every anatomical site. Strains 31, 33, 45, 52, and 58 also carry meaningful cancer risk and are included in the 9-valent vaccine.
How does HPV infection lead to cancer?
High-risk HPV strains produce oncoproteins called E6 and E7 that disable tumor suppressor proteins inside epithelial cells. Over 10 to 20-plus years, this allows the abnormal cells to accumulate genetic damage and become malignant.
Can HPV cause cancer in men?
Yes. Men develop the majority of HPV-positive oropharyngeal cancers and a meaningful share of anal cancers. Penile cancer is HPV-associated in about 60% of cases, and incidence in men has been rising as oropharyngeal rates climb.
How can cancer risk from HPV be reduced?
Vaccination through age 45 offers the strongest protection. Cervical screening with Pap and HPV co-testing every three to five years catches precancerous changes early. Condom use, smoking cessation, and limiting lifetime sexual partners all reduce the odds of persistent high-risk infection.
What are the symptoms of HPV-related cancers?
Symptoms vary by site: persistent sore throat or neck lump (oropharyngeal), anal bleeding or itching (anal), unhealed vulvar or penile lesions, and post-coital bleeding (cervical). Any symptom lasting beyond two weeks warrants prompt medical evaluation.
